SPOTLIGHT: Auxilium halts Phase III

Email LinkedIn
Tools


Auxilium shares this morning sank after it halted a late-stage trial for an injectable enzyme to determine why the freeze-dried material in its vials didn't appear to be correct. Release

Filed Under